Home > CIOE News > World's first COVID-19 inactivated vaccine on clinical trial

World's first COVID-19 inactivated vaccine on clinical trial

2020-04-15 09:26:17Source:Economy Observation

On April 12, after the approval of the clinical trial of the COVID-19 inactivated vaccine (Vero cells), the first phase of the Phase I clinical trial of COVID-19 vaccine was also launched in Henan province China. This vaccine is developed by SINOPHARM Wuhan institute of biological products Co., Ltd. 32 volunteers were eventually enrolled in the first phase of the clinical trial.

 d6ca7bcb0a46f21f4265f7e2dccbe9660d33ae20.jpeg

In the context of the absence of potent therapeutic drug against COVID-19, the development of related vaccines has received much attention. The approval of this inactivated vaccine for clinical trials means another step closer to the protection of the vaccine for the public.

 

The COVID-19 inactivated vaccine by SINOPHARM Wuhan institute of biological products Co., LTD has been approved by the National Medical Products Administration State Drug Administration’s approval for clinical trials.


This is the first COVID-19 inactivated vaccine in the world to receive clinical trial approval.

 

According to relevant national laws and regulations, SINOPHARM CNGB has been fully prepared for production and has the capacity to produce large-scale inactivated vaccines. It has declared that the clinical trial batch of the vaccine is around 50,000 doses with its annual production capacity will exceed 100 million doses after mass production.

 

Previously, SINOPHARM CNGB has developed molecular testing kits for the diagnosis of COVID-19, as well as technical standards and clinical treatment protocols for recovery plasma in recovering patients.

 

Source: Economy Observation